The new facility will offer manufacturing capacity for emerging compounds within the company’s oncology and immunology pipeline to serve markets globally.
Scheduled to be operational by 2019, the new facility will be the company’s first manufacturing presence in Asia.
The company already has other operations in Asia, which include research and development (R&D) functions in Tokyo and Shanghai as well as commercial operations throughout the region.
Currently, the company’s presence in Singapore includes 120 personnel supporting commercial operations, global R&D and general operations.
With the investment, the company intends to hire more than 250 new employees.
AbbVie senior vice president of Operations Azita Saleki-Gerhardt said," Our presence in Singapore will help assure geographic balance and continuity of product supply as well as increased capacity to deliver on our growing biologics and small molecule product pipeline."
The company is mainly focused on delivering its small molecule and biologics pipeline to address significant unmet medical needs and advance the wellbeing of patients across the following therapeutic areas: immunology, liver disease, oncology, neuroscience and kidney disease.
Singapore Economic Development Board director of Biomedical Sciences Kevin Lai said the investment is a testament of Singapore’s strong biologics manufacturing capabilities.
"To support the continued growth of this sector, Singapore will be investing heavily in human capital development, and new programs will be put in place to train biologics manufacturing talent ahead of demand," Lai said.